Harold Simmons Center for Chronic Disease Research and Epidemiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 West Carson Street, Torrance, CA 90502, USA.
Nat Rev Nephrol. 2012 Feb 28;8(5):284-92. doi: 10.1038/nrneph.2012.36.
Over the past two decades, most guidelines have advocated early initiation of dialysis on the basis of studies showing improved survival in patients starting dialysis early. These recommendations led to an increase in the proportion of patients initiating dialysis with an estimated glomerular filtration rate (eGFR) >10 ml/min/1.73 m(2), from 20% in 1996 to 52% in 2008. During this period, the percentage of patients starting dialysis with an eGFR ≥15 ml/min/1.73 m(2) increased from 4% to 17%. However, recent studies have failed to substantiate a benefit of early dialysis initiation and some data have suggested worse outcomes for patients starting dialysis with a higher eGFR. Several reasons for this seemingly paradoxical observation have been suggested, including the fact that patients requiring early dialysis are likely to have more severe symptoms and comorbidities, leading to confounding by indication, as well as biological mechanisms that causally relate early dialysis therapy to adverse outcomes. Patients with a failing renal allograft who reinitiate dialysis encounter similar problems. However, unique factors associated with a failed allograft means that the optimal timing of dialysis initiation in failed transplant patients might differ from that in transplant-naive patients with chronic kidney disease. In this Review, we discuss studies of dialysis initiation and compare risks and benefits of early versus late initiation and reinitiation of dialysis therapy.
在过去的二十年中,大多数指南都主张根据研究尽早开始透析,这些研究表明早期开始透析的患者生存率有所提高。这些建议导致了开始透析时估计肾小球滤过率(eGFR)> 10 ml/min/1.73 m(2)的患者比例增加,从 1996 年的 20%增加到 2008 年的 52%。在此期间,开始透析时 eGFR≥15 ml/min/1.73 m(2)的患者比例从 4%增加到 17%。然而,最近的研究未能证实早期透析开始的益处,并且一些数据表明,开始透析时 eGFR 较高的患者的预后更差。对于这种看似矛盾的观察结果,提出了几种原因,包括需要早期透析的患者可能有更严重的症状和合并症,导致指示性混淆,以及将早期透析治疗与不良结果因果相关的生物学机制。重新开始透析的衰竭肾移植患者也会遇到类似的问题。然而,与慢性肾脏病的移植初治患者相比,与移植失败相关的独特因素意味着衰竭移植患者开始透析的最佳时机可能有所不同。在这篇综述中,我们讨论了透析开始的研究,并比较了早期和晚期开始以及重新开始透析治疗的风险和益处。